http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2019216294-A1

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-396
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
filingDate 2019-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2021-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-WO2019216294-A1
titleOfInvention Azabenzimidazole compounds and pharmaceuticals
abstract An object of the present invention is to provide a compound having an M3 PAM action. Examples of the present invention include the azabenzoimidazole compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof. [Chemical 1] The compound of the present invention has M3 PAM activity. In addition, since the compound of the present invention has M3 PAM activity, it is useful as a preventive or therapeutic agent for dysuria and urinary storage disorder in hypoactive bladder, hypotonic bladder, non-contractile bladder, detrusor hypoactivity and neurogenic bladder. Is. [Selection diagram] None
priorityDate 2018-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467156259
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410437748
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID73553979
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465304458
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4486830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467090621
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466855917

Total number of triples: 42.